Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    745.67
    +0.38 (+0.05%)
     

  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     

  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     

  • Bitcoin GBP

    51,548.74
    +634.80 (+1.25%)
     

  • CMC Crypto 200

    1,373.58
    +60.96 (+4.64%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

RBC Capital Sticks to Their Hold Rating for Inovio Pharmaceuticals

Investing.com
·1-min read


RBC Capital analyst Gregory Renza maintained a Hold rating on Inovio Pharmaceuticals (NASDAQ:INO) on Monday, setting a price target of $9, which is approximately 24.37% below the present share price of $11.9.

Renza expects Inovio Pharmaceuticals to post earnings per share (EPS) of -$0.38 for the second quarter of 2020.

The current consensus among 7 TipRanks analysts is for a Moderate Buy rating of shares in Inovio Pharmaceuticals, with an average price target of $14.14.
The analysts price targets range from a high of $19 to a low of $8.

In its latest earnings report, released on 12/31/2019, the company reported a quarterly revenue of $279.49 thousand thousand and a net profit of -$30.42 million. The company's market cap is $1.88 billion.

ADVERTISEMENT

According to TipRanks.com, RBC Capital analyst Gregory Renza is a 5-star analyst with an average return of 54.2% and a 61.5% success rate.

Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. Its drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.